Vitamin D and Magnesium Aid Depression
Combined oral supplementation with magnesium plus vitamin D alleviates mild to moderate depressive symptoms related to long-COVID: an open-label randomized, controlled clinical trial.
We conducted a study to evaluate whether supplementing with magnesium and vitamin D could help alleviate mild-to-moderate depressive symptoms in individuals suffering from long-COVID. The clinical trial included 60 participants, aged 52.8 years on average, who had been diagnosed with hypomagnesemia, vitamin D deficiency, and mild-to-moderate depression.
Participants were divided into two groups: one received magnesium chloride along with vitamin D, while the other group only received vitamin D. Over four months, we monitored the effectiveness of these supplements in reducing depressive symptoms, using the Beck Depression Inventory (BDI) scale to measure changes.
Our results revealed a significant reduction in depressive symptoms for those taking both magnesium and vitamin D, with 73.2% of them reaching a positive outcome score on the BDI. In contrast, the control group, which received only vitamin D, showed a less dramatic improvement, suggesting that the combined treatment may offer more benefits for those struggling with depression related to long-COVID.
While both groups experienced some improvement, our findings indicate that magnesium plus vitamin D supplementation presents a promising option for individuals coping with depression in the wake of COVID-19.
Read More
Vitamin D supports depression management
Effects of cholecalciferol supplementation on depressive symptoms, C-peptide, serotonin, and neurotrophin-3 in type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial.
Putranto R, Setiati S, Nasrun MW, Witjaksono F, Immanuel S, et al. Effects of cholecalciferol supplementation on depressive symptoms, C-peptide, serotonin, and neurotrophin-3 in type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial. Narra J. 2024;4:e1342. doi:10.52225/narra.v4i3.1342
We conducted a double-blind, randomized, placebo-controlled trial to explore how cholecalciferol, a form of vitamin D, influences depressive symptoms in individuals suffering from type 2 diabetes mellitus (T2DM). This clinical study lasted for 12 weeks and involved participants who were either given a daily dose of 4000 IU of cholecalciferol or a placebo.
Throughout the study, we measured various factors, including the participants’ depression levels using the Beck Depression Inventory-II, as well as important biological markers like C-peptide, serotonin, and neurotrophin-3.
Our findings showed a significant reduction in depression scores among those taking cholecalciferol compared to the placebo group. Additionally, we observed a notable increase in C-peptide levels, which may indicate some metabolic benefits, although no significant changes were found in serotonin and neurotrophin-3 levels.
Ultimately, while cholecalciferol appears to alleviate mild to moderate depressive symptoms in T2DM patients through improved C-peptide levels, its impact on serotonin and neurotrophin-3 remains unclear. This highlights vitamin D as a potentially helpful option for managing depression alongside diabetes.
Read More
Calcitriol impacts depression positively
Calcitriol attenuates lipopolysaccharide-induced neuroinflammation and depressive-like behaviors by suppressing the P2X7R/NLRP3/caspase-1 pathway.
We explored how calcitriol, the active form of vitamin D3, impacts depression linked to neuroinflammation. Using a well-structured study with control and experimental groups, we examined the effects of calcitriol on mice exposed to lipopolysaccharide (LPS), a substance that induces depressive-like behavior and neuroinflammation.
During our experiments, we found that calcitriol not only reduced the inflammatory response in brain cells but also improved behavioral symptoms associated with depression. In particular, it lowered the levels of inflammation-related molecules while promoting anti-inflammatory ones in the brain's hippocampus, an area important for mood and memory.
We observed that calcitriol helped alleviate some of the negative behavioral effects triggered by LPS. The treatment also appeared to prevent the activation of microglia, the brain's immune cells, by interfering with a specific signaling pathway involved in inflammation.
Overall, our findings suggest that vitamin D3 could offer promising benefits as a treatment for depression by tackling neuroinflammation and protecting neuronal health.
Read More
Vitamin D3 shows antidepressant potential
Effect of Vitamin D3 on Depressive Behaviors of Rats Exposed to Chronic Unpredictable Mild Stress.
We looked at how vitamin D3 could help combat depression, especially in the context of chronic stress. The study involved 40 male Wistar rats, divided into different groups to compare the effects of vitamin D3, the antidepressant fluoxetine, and a combination of both.
The rats underwent 21 days of mild but unpredictable stress, simulating conditions often linked to depression. To measure the effects, we conducted several behavioral tests and collected blood samples to assess hormonal changes.
Results showed that vitamin D3 had a positive impact similar to fluoxetine on the rats' depressive behaviors. Specifically, we found that vitamin D3 improved results in key behavioral tests, suggesting it can help protect against stress-induced anxiety and depression.
Notably, the levels of corticosterone, a stress hormone, were lower in rats that received vitamin D3, indicating a protective effect. Overall, this study emphasizes the potential of vitamin D3 in alleviating depressive symptoms resulting from chronic stress.
Read More
Vitamin D3 improves depressive symptoms
Effects of vitamin D supplementation on depression and some selected pro-inflammatory biomarkers: a double-blind randomized clinical trial.
We conducted a double-blind randomized clinical trial to explore the effects of vitamin D3 supplementation on depression. Our study involved 56 adults with mild to moderate depression, who were assigned to either a vitamin D group or a placebo group. Over the course of eight weeks, the vitamin D group received a high dose of 50,000 IU cholecalciferol every two weeks, while the control group received a placebo.
After the treatment period, we observed that the participants who received the vitamin D3 experienced a significant reduction in depression severity, as measured by the Beck Depression Inventory-II. Interestingly, this improvement in mood occurred independently of any changes in inflammatory biomarkers like IL-1β, IL-6, and hs-CRP, which we also assessed during the study.
This indicates that while vitamin D supplementation may positively impact depressive symptoms, its effects are not directly linked to the inflammatory markers we evaluated. Our findings suggest that vitamin D3 could be a helpful addition to depression treatment strategies, particularly in individuals with low vitamin D levels.
Read More